Home
overview
SMi’s inaugural conference Antivirals, aims to cover the latest approaches in antiviral research, drug discovery and development. This conference will include presentations on the most virulent human viruses, including: HIV, Hepatitis, Respiratory Syncytial Virus, Herpes and SARS. In addition to this the possibility of broad spectrum antivirals will be discussed. We will also cover the challenges associated with antiviral research and how best to overcome them, with specific cases from the pharmaceutical industry.

A unique opportunity to learn from leading industry experts including:
Dr Giovanni Migliaccio, Senior Investigator, Merck
Sabine Hallenberger, Director, Virology Research, Bayer
Dr Akhter Molla, Senior Project Leader, Antiviral Drug Discovery, Abbott
Dr Daniel Lamarre, Associate Director, Biological Sciences, Boehringer-Ingelheim
Prof Ken Powell, Chief Executive Officer, Arrow Therapeutics
Dr Nathaniel Brown, Senior Vice President & Chief Medical Officer, Idenix
Dr Barney Koszalka, Senior Vice President, Corporate Strategy, Trimeris
Dr Peter Collins, Director, Virology & Research Toxicology, Shire
Dr Eddy Littler, Director, UK Site & Lead Discovery, Medivir
Dr Zhi Hong, Vice President, Drug Discovery, Ribapharm

Benefits of Attending:
· HIV, HERPES, INFLUENZA, HEPATITIS, RSV & SARS: Learn about the latest research in these therapeutic areas and where the approaches are leading
· STRATEGIES IN DEVELOPMENT: Understand the challenges of virology and the current strategies being used by leading pharmaceutical companies to overcome them
· NUCLEOSIDE ANALOGUES: Have they been exhausted? Hear the leading opinion of the direction of antiviral drug discovery
· HCV RESISTANCE: Evaluate the mechanisms of HCV resistance and hear about the current approaches to overcoming this threat
· NNRTI’s: Discover the current approaches to developing anti-AIDS drugs
· EMERGING VIRAL DISEASES: Hear about the types of emerging viral diseases and their identification

“A global forum dedicated to antivirals is long overdue in Europe, this exciting conference will definitely fill the gap..the line up of speakers and topics is excellent” Margaret Walsh, 2003

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Prof. Ken Powell

Prof. Ken Powell, Chief Executive Officer, Arrow Therapeutics

9:10 KEYNOTE ADDRESS

Dr Eddy Littler

Dr Eddy Littler, Director, UK Site & Lead Discovery, Medivir

  • Types of viral infections
  • Current antiviral therapies
  • Medivirs’ approach – novel nucleoside analogues
  • HIV resistance
  • The outlook for the antiviral market and antiviral therapies
  • 9:40 CHALLENGES OF ANTIVIRAL RESEARCH

    Dr Zhi Hong

    Dr Zhi Hong, Vice President, Drug Discovery, Ribapharm

  • Unmet medical needs important to major markets
  • Complexities of antiviral research
  • Moving compounds to clinical development: short-term and long-term strategies
  • Targetability of viral diseases: direct vs indirect approaches
  • Impact of drug resistance
  • Future therapies
  • 10:20 ANTIVIRAL THERAPIES, ANTIVIRAL STRATEGIES

    Sabine Hallenberger

    Sabine Hallenberger, Director, Virology Research, Bayer

  • Similarities, differences and unsolved problems
  • Treatment options in clinical development
  • Current research paradigms, new strategies and their hurdles
  • 11:00 Morning Coffee

    11:20 EMERGING VIRAL DISEASES

    Dr Paul Kellam

    Dr Paul Kellam, Senior Lecturer, University College London

  • Types of viral diseases
  • Emerging viral diseases
  • Virus identification methods, principles, application and limitations
  • Therapeutic target identification
  • Host and viral interactions
  • Broad spectrum antiviral therapies
  • 12:00 HIV REVERSE TRANSCRIPTASE AS A TARGET FOR ANTI-AIDS DRUGS

    Dr David Stammers

    Dr David Stammers, Reader, Structural Biology, University of Oxford

  • Nucleoside (NRTIs) and non-nucleoside RT inhibitors (NNRTIs)
  • First and second generation NNRTIs
  • Structural basis of drug resistance mechanisms for HIV RT
  • Structure based design of novel NNRTIs
  • 12:40 Networking Lunch

    14:00 NEW PARADIGM IN HIV PROTEASE INHIBITOR THERAPY

    Dr Akhter Molla

    Dr Akhter Molla, Senior Project Leader, Antiviral Drug Discovery, Abbott

  • Recent development in HIV protease inhibitor for the treatment of HIV
  • Resistance- cross resistance
  • Pharmacokinetics
  • Therapeutic options
  • 14:40 INTERLEUKIN-2 (IL-2)

    Dr Jill Leonard

    Dr Jill Leonard, Project Director, Kendle

  • Overview of literature
  • Role of IL-2 in HIV infection
  • IL-2 and analogues under investigation
  • On-going clinical research in IL-2 in HIV infection
  • The future of this area in antiretroviral therapies
  • 15:20 Afternoon Tea

    15:40 PROMISES AND REALITIES FOR HIV THERAPEUTICS

    Dr Barney Koszalka

    Dr Barney Koszalka, Senior Vice President, Corporate Strategy, Trimeris

  • The nature of HIV
  • Trends in treatment options
  • New targets – new opportunities
  • 16:20 ANTIVIRALS IN INFLUENZA

    Dr Simon Tucker

    Dr Simon Tucker, Director, Research, Biota Holdings

  • Epidemiology of Influenza and medical need
  • New directions and emerging opportunities for improved influenza management
  • 17:00 Chairman's Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Prof Ken Powell

    Prof Ken Powell, Chief Executive Officer, Arrow Therapeutics

    9:10 HERPES VIRUS- WHAT PROSPECTS BEYOND ACICLOVIR?

    Prof Vincent Emery

    Prof Vincent Emery, Professor of Virology, University College London

  • Discovery and attributes of aciclovir
  • Related compounds and their development
  • Progress against other targets
  • Market dynamics and issues
  • Challenges for the future
  • 9:40 HOST CELL APPROACHES TO HEPATITIS C

    Dr Bert Klebl

    Dr Bert Klebl, Vice President, Research, Axxima

  • Host cell targets for the treatment of Hepatitis C
  • Validation of novel target(s)
  • GI-GPx is down-regulated in replicon cells
  • Overexpression of GI-GPx suppresses RNA replication
  • Identification of compounds with clinical relevance that up-regulate the GI-GPx protein
  • 10:20 ANTI-HCV AGENTS AS PROMISING HEPATITIS C THERAPEUTICS

    Dr Michael Cordingley

    Dr Michael Cordingley, Director, Biological Sciences, Boehringer-Ingelheim

  • HCV disease in biology
  • HCV target-based drug discovery paradigm
  • Targets for therapeutic intervention in HCV-infected patients
  • NS3 protease inhibitor design
  • Discovery of BILN 2061
  • Biology and pharmacological profile of BILN 2061
    Human evaluation and antiviral effect of BILN 2061 in HCV-infected patients
  • 11:00 Morning Coffee

    11:20 HCV RESISTANCE TO ANTIVIRAL AGENTS

    Dr Giovanni Migliaccio

    Dr Giovanni Migliaccio, Senior Investigator, Merck

  • Rationale for HCV resistance studies
  • Experimental approach
  • Mutants resistant to inhibitors of the NS3 protease and NS5B polymerase
  • Replication fitness of resistant mutants
  • Mechanism of resistance
  • Structure-activity studies can help in developing resistance-repellent inhibitors
  • 12:00 PROSPECTS FOR NEW HEPATITIS THERAPIES

    Dr Nathaniel Brown

    Dr Nathaniel Brown, Senior Vice President & Chief Medical Officer, Idenix

  • The overall Hepatitis market
  • Which lines of research are the most promising?
  • The challenge in hepatitis and how these can be overcome
  • Case study
  • 12:40 Networking Lunch

    14:20 SMALL MOLECULE INHIBITORS OF RSV

    Malcolm Carter

    Malcolm Carter, Team Leader, Medicinal Chemistry, Arrow Therapeutics

  • A review of fusion inhibitors
  • Arrows’ approach
  • Novel inhibitors
  • Mechanism of action
  • Progress to full development
  • 15:00 SARS

    Dr Wade Blair

    Dr Wade Blair, Senior Virologist, Pfizer

  • Overview of SARS
  • Antiviral targets for intervention
  • Overview of current antiviral therapies
  • The outlook: 2003 and beyond
  • 15:40 Afternoon Tea

    16:00 PANEL DISCUSSION

    Dr J P Somadossi

    Dr J P Somadossi, Founder, Chief Executive Officer & Chairman, Idenix

    Prof Ray Schinazi

    Prof Ray Schinazi, Founder, Director & Scientific Advisor, Pharmassest

    Prof. Ken Powell

    Prof. Ken Powell, Chief Executive Officer, Arrow Therapeutics

    16:40 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.